New Enterprise Associates leads $35 mln round for NightstaRx
NightstaRx Ltd said Monday it raised $35 million in a Series B round led by New Enterprise Associates. Syncona, an independent subsidiary of the Wellcome Trust, also contributed to the round. London-based NightstaRx is a biopharmaceutical company that specializes in developing gene therapies for inherited retinal dystrophies.
10 November 2015•5 mins read
